- Home
- XPER vs VALN Comparison
XPER vs VALN Comparison
Compare XPER & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- VALN
- Stock Information
- Founded
- XPER 1990
- VALN 2012
- Country
- XPER United States
- VALN France
- Employees
- XPER N/A
- VALN N/A
- Industry
- XPER Semiconductors
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPER Technology
- VALN Health Care
- Exchange
- XPER Nasdaq
- VALN Nasdaq
- Market Cap
- XPER 463.5M
- VALN 510.7M
- IPO Year
- XPER 2003
- VALN 2021
- Fundamental
- Price
- XPER $6.68
- VALN $6.81
- Analyst Decision
- XPER Strong Buy
- VALN Strong Buy
- Analyst Count
- XPER 3
- VALN 2
- Target Price
- XPER $19.00
- VALN $16.00
- AVG Volume (30 Days)
- XPER 337.1K
- VALN 141.3K
- Earning Date
- XPER 05-07-2025
- VALN 05-06-2025
- Dividend Yield
- XPER N/A
- VALN N/A
- EPS Growth
- XPER N/A
- VALN N/A
- EPS
- XPER N/A
- VALN N/A
- Revenue
- XPER $493,688,000.00
- VALN $175,564,758.00
- Revenue This Year
- XPER $0.74
- VALN $19.17
- Revenue Next Year
- XPER $8.45
- VALN $26.31
- P/E Ratio
- XPER N/A
- VALN N/A
- Revenue Growth
- XPER N/A
- VALN 10.32
- 52 Week Low
- XPER $6.29
- VALN $3.62
- 52 Week High
- XPER $11.39
- VALN $9.50
- Technical
- Relative Strength Index (RSI)
- XPER 35.13
- VALN 50.97
- Support Level
- XPER $6.36
- VALN $6.59
- Resistance Level
- XPER $6.63
- VALN $7.30
- Average True Range (ATR)
- XPER 0.37
- VALN 0.47
- MACD
- XPER -0.00
- VALN 0.02
- Stochastic Oscillator
- XPER 22.08
- VALN 57.87
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.